Search Results

Avanos Medical, Inc. (NYSE: AVNS) today announced it has entered into a definitive agreement to acquire OrthogenRx, Inc., an emerging leader in viscosupplementation therapies for the treatment of knee osteoarthritis (OA) pain, for a total consideration of $160 million.

OrthogenRx®, Inc., a medical device company focused on the development and commercialization of treatments for knee pain caused by osteoarthritis (OA), today announced the company has surpassed 1 million in syringe distribution

OrthogenRx, Inc., a medical device company focused on the development and commercialization of treatments focused on the development and commercialization of treatments for knee pain caused by osteoarthritis (OA), today announced its

◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.

OrthogenRx®, Inc., a medical device company focused on the development and commercialization of treatments for musculoskeletal conditions, including osteoarthritis, announced it will showcase its new platform HARMOKNEE™ Customer Support Services, at the 2021 American Academy of Orthopaedic Surgeons Annual Meeting in San Diego, CA August 31- September 3, 2021.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

OrthogenRx, Inc. a medical device company focused on the development and commercialization of treatments for knee pain caused by osteoarthritis (OA), today announced new pricing options relating to The TriVisc Direct Purchase